Author: admin

  • Physicians embrace AI note-taking technology — Harvard Gazette

    Physicians embrace AI note-taking technology — Harvard Gazette

    AI-driven scribes that record patient visits and draft clinical notes for physician review led to significant reductions in physician burnout and improvements in well-being, according to a Mass General Brigham study of two large healthcare systems.

    The findings, published in JAMA Network Open, draw on surveys of more than 1,400 physicians and advanced practice providers at both Harvard-affiliated Mass General Brigham and Atlanta’s Emory Healthcare.

    At MGB, use of ambient documentation technologies was associated with a 21.2 percent absolute reduction in burnout prevalence at 84 days, while Emory Healthcare saw a 30.7 percent absolute increase in documentation-related well-being at 60 days.

    50% Physician burnout linked to maintaining electronic patient files

    “Ambient documentation technology has been truly transformative in freeing up physicians from their keyboards to have more face-to-face interaction with their patients,” said study co-senior author Rebecca Mishuris, chief medical information officer at MGB, a faculty member at Harvard Medical School, and a primary care physician in the healthcare system. “Our physicians tell us that they have their nights and weekends back and have rediscovered their joy of practicing medicine. There is literally no other intervention in our field that impacts burnout to this extent.”

    Physician burnout affects more than 50 percent of U.S. doctors and has been linked to time spent in electronic health records, particularly after hours. There is additional evidence that the burden and anticipation of needing to complete their appointment notes also contributes significantly to physician burnout.

    “Burnout adversely impacts both providers and their patients who face greater risks to their safety and access to care,” said Lisa Rotenstein, a co-senior study author and director of The Center for Physician Experience and Practice Excellence at Brigham and Women’s Hospital. She is also an assistant clinical professor of medicine at the UCSF School of Medicine. “This is an issue that hospitals nationwide are looking to tackle, and ambient documentation provides a scalable technology worth further study.”

    “Our physicians tell us that they have their nights and weekends back and have rediscovered their joy of practicing medicine.”

    Rebecca Mishuris, Mass General Brigham
     

    Qualitative feedback from users touted that ambient documentation enabled more “contact with patients and families,” improvements in their “joy in practice,” while recognizing its potential to “fundamentally [change] the experience of being a physician.” However, some users felt it added time to their note-writing or had less utility for certain visit types or medical specialties. Since the pilot studies began, the AI technologies have evolved as the vendors make changes based on user feedback and the large language models that power the technologies improve themselves through additional training, warranting continued study.

    The researchers analyzed survey data from pilot users of ambient documentation technologies at two large health systems. At Mass General Brigham, 873 physicians and advanced practice providers were given surveys before enrolling, then after 42 and 84 days. About 30 percent of users responded to the surveys at 42 days, and 22 percent at 84 days. All 557 Emory pilot users were surveyed before the pilots and then at 60 days of use, with an 11 percent response rate. Researchers analyzed the survey results quantifying different measures of burnout at Mass General Brigham and physician well-being at Emory Healthcare.

    The study authors added that given that these were pilot users and there were limited survey response rates, the findings likely represent the experience of more enthusiastic users, and more research is needed to track clinical use of ambient documentation across a broader group of providers.

    Mass General Brigham’s ambient documentation program launched in July 2023 as a proof-of-concept pilot study involving 18 physicians. By July 2024, the pilot, which tested two different ambient documentation technologies, expanded to more than 800 providers. As of April 2025, the technologies have been made available to all Mass General Brigham physicians, with more than 3,000 providers routinely using the tools. Later this year, the program will look to expand to other healthcare professionals such as nurses, physical and occupational therapists, and speech-language pathologists.  

    “Ambient documentation technology offers a step forward in healthcare and new tools that may positively impact our clinical teams,” said Jacqueline You, lead study author and a digital clinical lead and primary care associate physician at Mass General Brigham. “While stories of providers being able to call more patients or go home and play with their kids without having to worry about notes are powerful, we feel the burnout data speak similar volumes of the promise of these technologies, and importance of continuing to study them.”

    Ambient documentation’s use will continue to be studied with surveys and other measures tracking burnout rates and time spent on clinical notes inside and outside of working hours. Researchers will evaluate whether burnout rates improve over time as the AI evolves, or if these burnout gains plateau or are reversed.


    This project received financial support from the Physician’s Foundation and the National Library of Medicine of the National Institutes of Health.


    Continue Reading

  • Indian black scorpion venom holds key to new antidote

    Indian black scorpion venom holds key to new antidote

    [NEW DELHI, SciDev.Net] Researchers in India say they are close to creating an antivenom against the painful sting of the Indian black scorpion, which lurks in the undergrowth of the country’s forested areas.

    Although scorpion stings are a global health concern, scorpion venom has attracted limited scientific scrutiny, leading to a poor understanding of its complex composition and toxicity, say the researchers whose study will be published in the September issue of the International Journal of Biological Macromolecules.

    The glossy Indian black scorpion, or Heterometrus bengalensis, has inhabited the Earth for around 450 million years, and lives mainly in tropical and subtropical regions, including India, North Africa, Latin America, and the Middle East.

    “This is a first step towards the goal of an antivenom that is effective for more than one species.”

    Susmita Nath, researcher, Institute of Advanced Study in Science and Technology

    About 1.2 million scorpion sting incidents are reported globally each year, resulting in around 3,250 deaths.

    Delivered through a needle-like stinger at the tip of its long, flexible tail, scorpion venom can have severe side effects such as respiratory stress, cardiac dysfunction and multiple organ failure.

    Treatment usually requires injections of antivenom, which can be expensive.

    Currently, the standard treatment for scorpion sting, the F(ab’)2 antivenom, was developed by India’s state-run Haffkine Bio-Pharmaceutical Corporation to treat victims of the red scorpion (Buthus tamulus) sting.

    However, scientists began to question whether species-specific antivenoms may be needed for more effective treatment.

    Keep Science Journalism Alive

    SciDev.Net provides award-winning science news coverage free of charge. We rely on donations from readers like you to keep going.

    Donate to SciDev.Net today

    Processing ...

    “While the primary focus of our research was black scorpion venom profiling, it offers a production roadmap for a safe and effective antivenom, the creation of which is ongoing at our laboratory at the Institute of Advanced Study in Science and Technology (IASST), Guwahati,” says Susmita Nath, a member of the research team.

    “We have adequate initial data required to formulate and manufacture a viable antidote for H. bengalensis venom.”

    The study, spearheaded by Ashis K. Mukherjee, director of IASST, used spectrometry — the measurement of interactions between light and matter — and biochemical analysis to uncover 25 distinct toxins across eight protein families in the venom, the basis of its danger to prey and humans.

    Studying the effects of scorpion venom on Swiss albino mice, the researchers found that the chemicals led to systemic toxicity, increased liver enzymes, organ damage, and inflammation.

    The venom triggered a toxic storm in the mouse’s system, causing liver enzyme levels to skyrocket, says Mukherjee.

    “Organs showed signs of damage and the immune system went into overdrive — mounting a proinflammatory response that hinted at potential shock or severe allergic reactions in real-world stings,” he explained.

    The findings, said Mukherjee, show the complexity of the black scorpion venom and highlight the urgency of improving therapeutic strategies, including the development of targeted, species-specific antivenom.

    According to Mukherjee, scorpion venom is also being studied in other laboratories for its potential use in medicines. The venom contains peptides that can regulate the flow of ions in cells, act as an antimicrobial, or suppress the immune system to prevent it attacking healthy cells.

    “Our study provides the first full venom profile of H. bengalensis and links the discovered toxins to systemic pathogenic consequences in a mammal,” said Nath.

    “It lays a platform for further research into scorpion venom’s medicinal, toxicological, and ecological consequences, as well as helping to build a reference database of venom proteins for future investigations.”

    According to Nath, since scorpion venom composition is species-specific, further research is needed to create an antivenom that is effective for multiple scorpion species.

    “This is a first step towards the goal of an antivenom that is effective for more than one species,” she added.

    Y K Gupta, president of the Society of Toxicology, India and known for his work on scorpion venom, says the sting carries a “complex mixture of toxins” that can make treatment difficult.

    “Any work towards developing an effective antivenom for scorpion stings is therefore welcome,” said Gupta, who was not involved in the study.

    This piece was produced by SciDev.Net’s Global desk.


    Continue Reading

  • Alpha1H Demonstrates Clinical Benefit in NMIBC

    Alpha1H Demonstrates Clinical Benefit in NMIBC

    NMIBC | Image credit:

    © Adin – stock.adobe.com

    A phase 2 study (NCT03560479) evaluating Alpha1H for the treatment of patients with non–muscle-invasive bladder cancer (NMIBC) met its primary and secondary end points, according to an announcement from Hamlet BioPharma.1

    Final findings from the study revealed that approximately 80% of patients treated with Alpha1H experienced a response, with an average tumor size reduction in the high-dose group of 59%. Additionally, clinical benefit was observed in patients who received a second installation.

    The study also demonstrated that Alpha1H reached tumor tissue, triggered tumor cell apoptosis, and led to rapid shedding of tumor cells into the urine. Additionally, Alpha1H led to the downregulation of more than 700 of approximately 800 cancer-related genes, per RNA analysis. Investigators also noted a broad immune response with Alpha1H overlapping with BCG, except responses occurred more rapidly and without lasting adverse effects (AEs) compared with what is historically observed with BCG.

    Regarding safety, no serious treatment-related AEs were reported, including at higher dose levels or with repeat dosing. The incidence of mild, local AEs was similar between the Alpha1H and placebo arms. No systemic AEs were observed with Alpha1H, which is consistent with its local mechanism of action.

    Data from the final analysis of the study have been submitted to the FDA, and Hamlet BioPharma is coordinating with the regulatory agency on the design of a phase 3 study.

    “The final clinical report’s consistent efficacy outcomes and favorable safety profile are highly encouraging. The strength of the data provides compelling evidence of Alpha1H’s potential to become a much-needed proactive treatment option, and we look forward to advancing it in our regulatory discussions,” Catharina Svanborg, MD, PhD, chief executive officer of Hamlet BioPharma, stated in a news release. “We are committed to bringing this innovative therapy to patients as quickly and safely as possible. These results mark a major milestone for Hamlet BioPharma and for people with cancer in the urinary bladder. The study was made possible through close collaboration with leading universities and medical centers, including Lund University, Sweden, Motol University Hospital, Czechia and Linnane Pharma AB, whose combined expertise ensured robust design, execution, and analysis.”

    Alpha1H Background and Phase 2 Study Design

    Alpha1H is designed to form the Alpha1H complex by binding to oleic acid; in preclinical and animal models, the agent has demonstrated the ability to kill a various cancer cells, including the inhibition of tumor development in a bladder cancer model.2

    In the phase 2 study, investigators enrolled patients at least 18 years of age with non-muscle invasive papillary bladder cancer per cystoscopy appearance and were slated to undergo transurethral resection of bladder tumor (TURBT).3 Patients needed retain bladder content for at least 1 hour.

    Key exclusion criteria comprised a history of muscle-invasive bladder cancer; a history of NMIBC with an interval shorter than 6 months after previous TURBT; treatment with intravesical BCG or chemotherapy within 12 months of enrollment; any other cancer diagnosis within the last 5 years; acute urinary tract infection; and prior radiotherapy or systemic chemotherapy.

    In the main part of the study, patients were randomly assigned to received Alpha1H at 7.4 mg/mL or placebo on days 1, 3, 5, 8, 15 and 22 of a single cycle. During an open-label dose-escalation portion, Alpha1H was also given at daily doses of 37 mg/mL and 74 mg/mL.

    Safety, efficacy of cell shedding, and changes in papillary characteristics. Secondary end points included induction of apoptosis, histopathology scoring, and tumor response to Alpha1H by gene expression analysis.1

    References

    1. Hamlet BioPharma announces the completion of the Alpha1H phase II study in non-muscle invasive bladder cancer. News release. Hamlet BioPharma. August 21, 2025. Accessed August 21, 2025. https://hamletbiopharma.com/hamlet-biopharma-announces-the-completion-of-the-alpha1h-phase-ii-study-in-non-muscle-invasive-bladder-cancer/
    2. Alpha1H. Hamlet BioPharma. Accessed August 21, 2025. https://hamletbiopharma.com/cancer/alpha1h-2/
    3. A first-in-human study of alpha1H in patients with non-muscle invasive bladder cancer. ClinicalTrials.gov. Updated August 19, 2020. Accessed August 21, 2025. https://clinicaltrials.gov/study/NCT03560479

    Continue Reading

  • European Commission Approves Zanubrutinib Tablet Formulation for All Indications in B-Cell Malignancies

    European Commission Approves Zanubrutinib Tablet Formulation for All Indications in B-Cell Malignancies

    B-Cell Malignancies | Image
    Credit: © Bipul Kumar
    – stock.adobe.com

    The European Commission has approved a tablet formulation of zanubrutinib (Brukinsa) for use in all previously authorized indications of the capsule formulation.1

    This follows the FDA’s approval of the tablet formulation in June 2025.2

    Zanubrutinib is approved in the European Union in the following indications:3

    • as monotherapy for the treatment of adult patients with Waldenström macroglobulinemia who have received at least 1 prior therapy, or in first-line treatment for patients unsuitable for chemoimmunotherapy.
    • as monotherapy for the treatment of adult patients with marginal zone lymphoma who have received at least 1 prior anti-CD20-based therapy.
    • as monotherapy for the treatment of adult patients with chronic lymphocytic leukemia
    • in combination with obinutuzumab (Gazyva) for the treatment of adult patients with refractory or relapsed follicular lymphoma who have received at least 2 prior systemic therapies

    Notably, in the United States, zanubrutinib is also approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy; however, zanubrutinib does not hold any MCL indications in the European Union (EU).3,4

    The recommended dose of the tablet formulation reflects that of the capsule formulation at 320 mg per day.1 Each tablet is 160 mg, allowing patients to take 2 tablets daily instead of 4 80-mg capsules.

    “Developed to meet the real-world needs of patients, the new [zanubrutinib] tablet formulation aims to simplify treatment, reduce pill burden, and enhance ease of administration, reflecting our continuous focus on patient-centered innovation,” Giancarlo Benelli, senior vice president and head of Europe at BeOne Medicines, stated in a news release. “With more than 200,000 patients treated globally and the broadest label of any BTK inhibitor in Europe, zanubrutinib’s differentiated clinical profile continues to make an impact for people facing certain B-cell cancers.”

    Safety Overview

    Compiled safety data in the zanubrutinib European Union prescribing information show that most common occurring adverse effects reported in at least 20% of patients treated with zanubrutinib monotherapy (n = 1550) included upper respiratory tract infection(36%), bruising (32%), hemorrhage/hematoma(30%), neutropenia(30%), musculoskeletal pain(27%), rash(25%), pneumonia(24%), diarrhea (21%), and cough(21%).3

    The most common grade 3 or higher AEs that occurred in at least 3% of patients comprised neutropenia (21%), pneumonia (14%), hypertension (8%), thrombocytopenia (6%), anemia (6%), and hemorrhage/hematoma (4%). AEs led to treatment discontinuation of zanubrutinib monotherapy in 4.8% of patients, with the most common being pneumonia(2.6%). AEs led to dose reductions in 5.0% of patients.

    In the phase 2 ROSEWOOD trial (NCT03332017), among patients with relapsed/refractory follicular lymphoma treated with zanubrutinib in combination with obinutuzumab (n = 143), the most common AEs reported in at least 20% of patients included thrombocytopenia(37%), neutropenia(31%), and fatigue(27%). Grade 3 or higher AEs reported in more than 3% of patients included neutropenia§ (25%), thrombocytopenia(16%), pneumonia(15%), and anemia (5%). AEs led to treatment discontinuation in 4.9% of patients, with the most common being pneumonia (4.2%). AEs led to dose reduction in 7.0% of patients.

    References

    1. The European Commission has approved a tablet formulation of BeOne Medicines’ Brukinsa for use across all of its previously authorized indications. News release. BeOne Medicines. August 21, 2025. Accessed August 21, 2025. https://ir.beonemedicines.com/news/european-commission-approves-tablet-formulation-of-beone-medicines-brukinsar-for-all-approved-indications/60a73cd1-3e95-46b4-b377-578f401440b9
    2. U.S. FDA approves tablet formulation of BeOne’s Brukinsa for all approved indications. News release. BeOne. June 11, 2025. Accessed August 21, 2025. https://www.businesswire.com/news/home/20250611860939/en/U.S.-FDA-Approves-Tablet-Formulation-of-BeOnes-BRUKINSA-for-All-Approved-Indications
    3. Brukinsa. European Medicines Agency. Accessed August 21, 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa
    4. Brukinsa. Prescribing information. BeOne. Updated June 2025. Accessed August 21, 2025. https://beonemedicines.us/PDF/BRUKINSAUSPI.pdf

    Continue Reading

  • Egypt retrieves parts of 2,000-year-old sunken city off coast of Alexandria | Egypt

    Egypt retrieves parts of 2,000-year-old sunken city off coast of Alexandria | Egypt

    Egypt has unveiled parts of a sunken city submerged beneath waters off the coast of Alexandria, revealing buildings, artefacts and an ancient dock that date back more than 2,000 years.

    Egyptian authorities said the site, located in the waters of Abu Qir Bay, may be an extension of the ancient city of Canopus, a prominent centre during the Ptolemaic dynasty, which ruled Egypt for nearly 300 years, and the Roman empire, which governed for about 600 years.

    Over time, earthquakes and rising sea levels submerged the city and the nearby port of Heracleion.

    Divers helped to retrieve statues from the depths of the sunken city and cranes hoisted the artefacts on to dry land. Photograph: Khaled Desouki/AFP/Getty Images

    On Thursday, cranes slowly hoisted statues from the depths while divers in wetsuits, who had helped retrieve them, cheered from the shore.

    Egypt’s tourism and antiquities minister, Sherif Fathi, said: “There’s a lot underwater, but what we’re able to bring up is limited, it’s only specific material according to strict criteria.

    “The rest will remain part of our sunken heritage.”

    The underwater ruins include limestone buildings that may have served as places of worship, residential spaces and commercial or industrial structures.

    Reservoirs and rock-carved ponds for domestic water storage and fish cultivation were also uncovered.

    Only specific material is allowed to be retrieved from the underwater city. The rest will remain submerged. Photograph: Amr Nabil/AP

    Other notable finds include statues of royal figures and sphinxes from the pre-Roman era, including a partially preserved sphinx with the cartouche of Ramses II, one of the country’s most famous and longest-ruling ancient pharaohs.

    Many of the statues are missing body parts, including a beheaded Ptolemaic figure made of granite, and the lower half of a Roman nobleman’s likeness carved from marble.

    A merchant ship, stone anchors and a harbour crane dating back to the Ptolemaic and Roman eras were found at the site of a 125-metre dock, which the ministry said was used as a harbour for small boats until the Byzantine period.

    Notable finds include statues of royal figures and sphinxes from the pre-Roman era. Photograph: Khaled Desouki/AFP/Getty Images

    Alexandria is home to countless ancient ruins and historic treasures, but Egypt’s second city is at risk of succumbing to the same waters that claimed Canopus and Heracleion.

    The coastal city is especially vulnerable to the climate crisis and rising sea levels, sinking by more than 3mm every year.

    Even in the United Nations’ best-case scenario, a third of Alexandria will be underwater or uninhabitable by 2050.

    Continue Reading

  • Raindrops in the Sun’s corona captured in ultra-high-definition

    Raindrops in the Sun’s corona captured in ultra-high-definition

    A new way of steadying telescopes has lifted the blur on the sun’s corona, giving scientists crisp, movie-like views of structures only dozens of miles across for the first time.

    The system, called adaptive optics for the corona, reaches roughly 39 miles of detail at the sun’s distance and tracks fast changes that shape space weather.


    These images reveal fine threads of cooling plasma, twisting arcs called prominence structures, and a narrow, short lived plasmoid that unraveled in the wake of a flare.

    The footage is not a special eclipse trick, it is routine observing from a ground telescope that now corrects Earth’s air in real time.

    Why the Sun’s corona matters

    Lead scientist Dirk Schmidt of the U.S. National Science Foundation’s National Solar Observatory led development on the Goode Solar Telescope at Big Bear, with collaborators at New Jersey Institute of Technology’s Center for Solar Terrestrial Research (CSTR). 

    Clearer views at small scales help answer long standing questions about why the corona is millions of degrees while the surface below is about 10,000 degrees, a puzzle known as the coronal heating problem. 

    Spacecraft imagers like the Atmospheric Imaging Assembly on NASA’s Solar Dynamics Observatory (SDO-AIA) catch the full disk with 1.5 arcsecond resolution and 12 second cadence, but they do not reach the fine angular resolution a large ground telescope can achieve with good correction.

    The new approach narrows the gap and exposes the tiny strands and clumps that models of loop heating and cooling have hinted at for years.

    New optics beat the blur

    “The turbulence in the air severely degrades images of objects in space, like our sun, seen through our telescopes. But we can correct for that,” said Schmidt.

    The Coronal Adaptive Optics system (CONA) reshapes a mirror about 2,200 times per second and uses a specialized sensor tuned to hydrogen-alpha light to lock onto off limb features that older systems could not stabilize. 

    Older solar adaptive optics worked best on the bright disk, yet lost their grip beyond the edge where the corona glows faintly.

    CONA was built to track dim coronal structure directly, so the correction follows the exact region of interest instead of a nearby proxy, which keeps the scene stable for fast imaging bursts.

    At the telescope’s diffraction limit near one tenth of an arcsecond, the team resolved strands under 100 kilometers wide and captured a finely twisted plasmoid that formed and collapsed during the decay phase of a modest flare.

    Those behaviors point to rapid changes in magnetic topology known as magnetic reconnection, a process that can spawn small islands and kinks as energy is released in bursts.

    What the Sun’s coronal rain reveals

    The instrument’s sharpness turned coronal rain from a blur into a structured pattern, with many strands clustering near the telescope’s resolution limit and others appearing even narrower in the raw profiles.

    That is important because rain offers a direct marker of how and where energy is deposited along coronal loops, and models predict a wide range of sizes and cooling times tied to the heating pattern.

    “Raindrops in the sun’s corona can be narrower than 20 kilometers,” concluded Thomas Schad, NSO astronomer on the observing team, from the most detailed images of coronal rain to date.

    Rain forms when hot loop plasma becomes thermally unstable and condenses, a multiphase process that has been linked to the balance between heating and cooling in simulations and observations of active regions.

    Examples of diverse Hα features outside the solar disk imaged with adaptive optics correction. Credit: Nature Astronomy
    Examples of diverse Hα features outside the solar disk imaged with adaptive optics correction. Click image to enlarge. Credit: Nature Astronomy

    Surprise twist in a flare’s wake

    During one observing run, the team watched a narrow, fast evolving plasmoid appear near the apex of post flare loops and then unravel into fragments within minutes, an event that would have looked bland at lower resolution and cadence.

    The feature’s fine threads and abrupt halt suggest a tug of war between tension and pressure that accompanies reconnection and kink like behavior in the surrounding field, classic magnetohydrodynamics at work.

    “These are by far the most detailed observations of this kind, showing features not previously observed, and it’s not quite clear what they are,” said Vasyl Yurchyshyn, NJIT CSTR research professor and co-author of the study.

    That uncertainty is useful, it points directly to the scales where models must improve and where future spectroscopic measurements can pin down temperatures and flows.

    Sun’s corona and new telescopes

    CONA now runs at the Goode Solar Telescope in California, and the team is preparing to bring the technique to the 4 meter Daniel K. Inouye Solar Telescope in Hawai‘i, which would push the smallest observable scales even further.

    Pairing high resolution imaging with polarimetry at that aperture would open the door to routine measurements of coronal magnetic fields and their rapid changes.

    A move to larger apertures also raises the bar for speed, because features can evolve significantly in fractions of a second.

    That is a tradeoff the field is ready to make now that coronal adaptive optics is turning ultra fine structures from theory into everyday data.

    The study is published in Nature Astronomy.

    —–

    Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

    Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

    —–

    Continue Reading

  • PS5 Prices Go Up Today. Here’s How Much and Why

    PS5 Prices Go Up Today. Here’s How Much and Why

    Sony will increase the prices of its PlayStation 5 consoles in the US, starting today. This follows the trend of console manufacturers such as Microsoft and Nintendo raising prices for their hardware in response to tariffs. 

    The PlayStation-maker posted about the price change Wednesday. The jump in price is $50 more than the current price for each model.

    The new prices are:

    “Similar to many global businesses, we continue to navigate a challenging economic environment,” Sony said in a post about the price increase. 

    As of Thursday morning, retailers and Sony’s online store have yet to update the console prices. This jump in price also will likely affect recently released PS5 bundles such as the Astro Bot bundle and Fortnite Cobal bundle

    Sony says accessories have not been affected by the change and this cost hike only affects the US. 

    In May, Microsoft increased the price of the Xbox Series consoles and Nintendo hiked the original Switch console price and Switch 2 accessories this month.

    While the companies didn’t point to the tariffs instituted by President Donald Trump as the reason for the hardware price jump, it would explain the trend in recent months. 

    Watch this: Unboxing the PlayStation 5 Pro 30th Anniversary Collection


    Continue Reading

  • Ebrechi Eze – how Arsenal won the race for the Crystal Palace forward

    Ebrechi Eze – how Arsenal won the race for the Crystal Palace forward

    It all happened in a few whirlwind hours.

    Earlier on Wednesday, it looked as though the 27-year-old Eze would be heading to the white side of north London.

    But the deal was not completed.

    And the reason was Palace’s Europa Conference League play-off match with Fredrikstad on Thursday.

    The Eagles wanted to keep Eze for a game they view as pivotal to their season, and one they did not want to tackle without having a replacement in place.

    Palace manager Oliver Glasner was strong in his pre-match press conference saying that Eze and Marc Guehi, who has also been linked with a move away, were ‘committed’ to the team.

    Over at the Emirates Stadium a sub plot was brewing.

    Arsenal were holding an open training session at their ground which did not feature Kai Havertz. It was later revealed the German international was being assessed for a knee injury.

    Despite the exact severity of the injury being unclear, Arsenal knew enough to make a move.

    Hours later on Wednesday afternoon, Arsenal bid for Eze, deciding to act on their long-standing interest in the player.

    With Eze being a boyhood Arsenal fan who played in their academy, it was an easy decision for the player.

    By 19:30 BST the news of the transfer swoop emerged in the media, with sources briefing that there was nothing Spurs could have done to make the transfer happen due to that emotional connection.

    And that element – Eze turning down Tottenham – is sure to make him an instant fan favourite at Arsenal.

    Why did they leave it so late?

    Arsenal had seen Eze as more of a number 10 and, with Ethan Nwaneri securing his future to the club with a long-term contract, they had to think carefully about exactly how the England international would fit in.

    But it seems the Havertz injury meant they decided he was needed in their squad after all.

    It is currently unclear if Eze will still play in the Europa Conference play-off for Palace on Thursday.

    But, should he come through that game unscathed, he is certain to sign for the Gunners in the next few days, completing a full-circle moment in re-joining the club he was released by at 13.

    Continue Reading

  • Better sleep could help reduce risk of self-harm in teenagers

    Better sleep could help reduce risk of self-harm in teenagers

    Adolescents who experience sleep problems are more likely to self-harm, according to a study of over 10,000 teenagers.

    Researchers found that poor or fragmented sleep at age 14, including shorter sleep on school days, longer time to fall asleep and more frequent night awakenings, predicted a higher risk of self-harm three years later. 

    Published in the Journal of Child Psychology and Psychiatry, the study comes as self-harm among young people continues to rise, representing a growing public health concern. The findings show that sleep, a modifiable risk factor, is a key influence and improving sleep during adolescence, a critical period for intervention, could help reduce the risk of self-harm.

    Related Article: Study reveals successful mental health interventions for school-aged children

    Led by researchers at the University of Warwick and University of Birmingham, the team analysed data from 10,477 teenagers in the Millennium Cohort to investigate the relationship between multiple measures of sleep problems and rates of self-harm.

    At the age of 14, the teenagers were asked about their sleep patterns, including how long they slept on school days, how long it took to fall asleep, and how often they awoke during the night. They were also asked whether they had self-harmed at 14, and were asked the same question again three years later, at age 17.

    Teenagers who slept less on school nights, took longer to fall asleep or woke up more often at night, were more likely to report self-harming at age 14. These sleep problems also predicted higher rates of self-harm three years later at age 17, even after accounting for factors such as age, sex, socioeconomic background, and mental health.

    The findings highlight that teenage sleep can have long-lasting impacts on self-harm, suggesting that sleep interventions during adolescence could be a way to support teenagers at risk.

    Michaela Pawley, PhD student at the University of Warwick, and first author, said: ‘Using large-scale data like this really allows you to explore longitudinal relationships at a population level. In this analysis, we discovered that shorter sleep on school days, longer time to fall asleep and more frequent night awakenings at age 14 associated with self-harm concurrently and 3 years later at age 17.’

    Related Article: Study reveals teenage girls’ own views on low mood and anxiety increase

    She added: ‘While this is clearly an unfavourable relationship, one positive from this research is that sleep is a modifiable risk factor, we can actually do something about it. If the link between sleep and self-harm holds true and with well-placed interventions in schools and homes, there is a lot we can do to turn the tide.’

    The researchers also looked at whether poor sleep can lead to poor decision-making, but found that this did not explain the relationship between sleep problems and self-harm. Night awakenings may be particularly important, as they disrupt REM sleep, which is essential for emotion regulation. Additionally, disturbed sleep may lead to ineffective coping strategies and impaired cognitive function.

    Further research is needed to determine how poor sleep is associated with the risk of self-harm. Regardless of the cause, the study emphasises the importance of sleep in adolescence in preventing self-harming behaviours.

    Related Article: Text message reminders can improve teenage oral health

    Senior author Professor Nicole Tang, director of Warwick Sleep and Pain Lab at The University of Warwick, added: ‘Self-harm is one of the leading causes of death among adolescents and young adults. It is a sobering topic. Knowing that poor and fragmented sleep is often a marker preceding or co-occurring with suicidal thoughts and behaviour, it gives us a useful focus for risk monitoring and early prevention.’

     

    Continue Reading

  • Victoria’s mountain ash forests could lose a quarter of ‘giant’ trees as temperatures rise | Environment

    Victoria’s mountain ash forests could lose a quarter of ‘giant’ trees as temperatures rise | Environment

    Victoria’s mountain ash forests are thinning rapidly as the globe heats up, and could lose a quarter of their “giant” trees that grow up to 80m tall in the coming decades, research has found.

    Forests of Eucalyptus regnans – one of the tallest tree species in the world – lose about 9% of their trees for every degree of warming, according to a University of Melbourne-led study published in Nature Communications.

    “These are giants,” said lead author Dr Raphael Trouve. “They are the tallest flowering plant on Earth – that means they regularly reach 60 to 80m tall.”

    The researchers analysed data collected from mountain ash forests over more than 50 years to determine tree mortality rates and forest carrying capacity – the maximum number of trees of a given size that the forest can sustain.

    They found that forests growing in the warmest conditions had the lowest carrying capacity, which further decreased with rising temperatures.

    Eucalyptus regnans lose about 9% of their trees for every degree of warming, research has found. Photograph: University of Melbourne

    “We found that for each extra degree of temperature, the number of trees that the forest can sustain drops by 9%,” Trouve said. “By 2080 – with three extra degrees, as we expect – that tallies up to around a quarter of the trees gone.”

    The estimated forest loss did not include the additional impact of bushfires, which are expected to grow in severity as the earth warms up.

    The forest thinning was thought to be the result of increased competition for limited resources. “A growing tree needs space and resources to survive,” Trouve said. “Under resource-limited conditions, such as water stress, a big tree will outcompete smaller, surrounding trees, causing their deaths.”

    Changes in forest carrying capacity would likely have knock-on effects. “Its not just about trees, it’s about the carbon they store, the planet we need, the water we drink,” he said.

    Mountain ash forests are considered one of the Earth’s most carbon-dense ecosystems, storing more carbon per hectare than the Amazon. But as more trees died and decomposed, the forests would eventually shift from carbon sinks into sources of emissions, the study said.

    skip past newsletter promotion

    “Climate change is stressing forests all over the world, and that can be exacerbating the rate of thinning” said Dr David Bowman, a professor of fire science at the University of Tasmania with a background in eucalypt ecology, who was not involved in the study.

    Bowman said climate change – and the combination of heatwaves, rising temperatures and chronic droughts – was placing forests under enormous stress globally, and particularly affected those in mid-latitude, temperate environments.

    Giant trees were particularly vulnerable. “They’re getting exhausted,” he said.

    Then, as forests were dying and thinning, they became more open and more flammable, as fuel – in the form of leaf matter, litter, fine branches and stems – accumulated in the forest.

    The risk of bushfire then became a “nightmare scenario” for large trees – already struggling to survive – which would struggle to recover.

    Continue Reading